Q2 2025 Earnings Call Transcript July 24, 2025 Lazard Ltd beats earnings expectations. Reported EPS is $0.52, expectations ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

From AI integration to workforce development, health system marketing leaders are making targeted investments in 2025 aimed at boosting engagement, strengthening strategy alignment and driving ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Q2 2025 Earnings Call Transcript July 23, 2025 Thermo Fisher Scientific Inc. beats earnings expectations. Reported EPS is ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...